Highest-materiality recent filing
InfuSystem Q1 net rev $33.7M (-3% YoY); net income $1.0M vs prior loss
Patient Services rev $22.1M (+6% YoY); wound care revenue more than doubled to $2.1M.
InfuSystem reports record 2025 revenue $143.4M, adj. EBITDA $31.5M, net leverage 0.52x
2025 net revenue $143.4M, up 6.3% YoY from $134.9M; seven consecutive years of record revenue.
InfuSystem Reports Seventh Consecutive Year of Record Net Revenues of $143.4M, Net Income Up 183%
Full year net revenues $143.4 million, a 6% increase over prior year.
InfuSystem gets CMS separate payment for two pain pumps under NOPAIN Act starting Jan 2026
CMS added CADD-Solis (ICU Medical) and Sapphire (Eitan Medical) pumps to qualifying list for separate payment.
InfuSystem TTM revenue $141.1M, AEBITDA $30.2M; guides 6-8% FY2025 growth
TTM revenue through Sep 30, 2025: $141.1M; estimated 2025 revenue grows 6-8% over 2024's $134.9M.
InfuSystem Q3 2025 revenue $36.5M (+3% YoY), net income $2.3M (+25%), reaffirms 2025 guidance
Net revenues $36.5M (record), up 3% vs. $35.3M a year ago; Patient Services up 8%, Device Solutions down 3%.
Net revenue $36.0M (+7% YoY); Patient Services $21.5M (+6%), Device Solutions $14.5M (+8%).
InfuSystem provides FY2025 outlook: 8-10% revenue growth, high-teens AEBITDA margin
TTM revenue to March 31, 2025: $137.6M; TTM adj. EBITDA $27.8M (leverage 0.98x).
InfuSystem Q1 revenue $34.7M (+9% YoY); Adj. EBITDA $6.3M (+64%)
Net revenue $34.7M (+9% YoY); net loss narrowed to $0.3M ($0.01 loss per share) from $1.1M.
InfuSystem CEO Richard DiIorio to step down; Carrie Lachance named new CEO effective May 19, 2025
Richard DiIorio to step down as CEO effective May 19, 2025; separation not due to any disagreement with the Company.
Q4 net revenues $33.8M (+7% YoY); net income $0.9M ($0.04 EPS) vs $0.1M prior year.
InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M
TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).
InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%
Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).
SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.
Net revenues $33.7M (+6% YoY); net income $0.7M ($0.03 diluted EPS) vs $0.4M ($0.02) prior year.
InfuSystem signs 3-year distribution pact with Smith+Nephew for NPWT system
Three-year agreement to distribute Smith+Nephew's RENASYS EDGE negative pressure wound therapy system.
InfuSystem projects 2024 revenue of $134.2M and adjusted EBITDA of $26.5M
2023 revenue $125.8M (12% CAGR over 5 years); adjusted EBITDA $22.4M.
InfuSystem reports Q1 revenue up 5% to $32.0M; net loss widens, reaffirms guidance
Net revenues of $32.0M (+5% YoY); record quarterly revenue.
InfuSystem warned by NYSE American for failing to file 2023 10-K on time
Received NYSE American non-compliance notice due to failure to file 2023 Annual Report by April 1, 2024.
FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).
Director Malhotra resigns from InfuSystem Board; company pays $625K under cooperation pact
R. Rimmy Malhotra resigned from the Board effective March 8, 2024; no disagreement cited.
the newly constituted Board of Directors elected Beverly Huss to serve as the Chairman of the Board of Directors.
The Second Amended Agreement reflects changes in Ms. Lachance’s compensation and other terms of employment in connection with her previously announced transition from President and Chief Operating Officer of the Company to President and Chief Executive Officer of the Company that occurred on May 19, 2025.
Following the Annual Meeting, the newly constituted Board of Directors elected Ronald Hundzinski to serve as the Chairman of the Board of Directors and disbanded the role of Executive Chairman.
Coincident to Ms. Lachance's appointment, Scott Shuda was appointed Executive Chairman of the Company's Board.
The Board has appointed Carrie Lachance as the new CEO, effective as of the Separation Date.
Mr. DiIorio will step down as the Company's Chief Executive Officer ("CEO"), effective May 19, 2025
will continue to serve on the Board until the end of his term, which expires May 15, 2025
elected Ron Hundzinski to fill the vacancy created by this increase in size of the Board of Directors.
accepted the resignation of Mr. R. Rimmy Malhotra as a member of the Board, effective March 8, 2024
On March 24, 2023 , Christopher Sansone notified InfuSystem Holdings, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors
On September 20, 2022 , the Board of Directors of InfuSystem Holdings, Inc. (the “Company”) expanded the size of the Board of Directors from seven to eight members and elected R. Rimmy Malhotra to fill the vacancy created by this increase in size of the Board of Directors.
Max materiality 0.90 · Median 0.55 · Most common event other_material